Monitor the upLIFT topline data in mid-December 2026, which is the next major catalyst. The pre-BLA meeting request for congenital HI will also be a key regulatory milestone to watch.
Price Chart
Executive Summary
Rezolute filed an 8-K furnishing a corporate investor presentation. The presentation highlights $108 million in cash with runway through Q1 2028, a combined $5B+ U.S. market opportunity for its lead asset ersodetug in congenital hyperinsulinism and tumor hyperinsulinism, and key upcoming catalysts: topline data from the Phase 3 upLIFT study in tumor HI expected mid-December 2026 and a BLA filing for congenital HI targeted for 2027. The Phase 3 sunRIZE study in congenital HI missed its primary endpoint but showed clinically meaningful reductions on secondary CGM endpoints, and the FDA encouraged the company to request a pre-BLA meeting.
Key Facts
- Cash position of $108 million with runway through Q1 2028.
- Combined U.S. market opportunity estimated at $5B+ (congenital HI ~$750M-$1B TAM, tumor HI ~$4-$5B TAM).
- Phase 3 sunRIZE study in congenital HI: primary endpoint (SMBG weekly hypoglycemia events) not met; secondary CGM endpoint showed clinically meaningful reductions but not statistically significant at Week 24 ( -32%; p=0.30 at 10 mg/kg).
- FDA reviewed additional sunRIZE data and encouraged the company to request a Type B pre-BLA meeting for congenital HI.
- Phase 3 upLIFT study in tumor HI: topline results expected mid-December 2026; interim data showed 7 of 8 initial participants met the primary endpoint and achieved complete discontinuation of IV glucose.
- Ersodetug has Breakthrough Therapy Designation from FDA and Orphan Drug Designation in US and EU for congenital HI; Orphan Drug Designation for tumor HI.
- Pipeline includes GI-surgery hypoglycemia program with regulatory discussions expected in 1H 2027.
Financial Impact
$108 million cash; $5B+ combined U.S. TAM across congenital and tumor HI indications
Risk Factors
- Phase 3 sunRIZE study missed its primary endpoint; regulatory path for congenital HI BLA remains uncertain despite FDA encouragement.
- upLIFT study is single-arm, open-label with a small sample size (n=~16); positive interim results may not replicate in the full dataset.
- No revenue or profitability data provided; company is pre-commercial with significant execution risk.
- Forward-looking statements regarding market size, pricing, and regulatory timelines are unvalidated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-120205 |
| Document: tm2628517d1_8k.htm | 0001104659-26-120205 |
| Document: 0001104659-26-120205-index-headers.html | 0001104659-26-120205 |
| Document: 0001104659-26-120205-index.html | 0001104659-26-120205 |
| Document: 0001104659-26-120205.txt | 0001104659-26-120205 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $4.20 | awaiting T+20 | awaiting T+20 | $3.95 (−5.95%) |
Oct 28, 2026 4d ago | SC 13G | $4.22 | awaiting T+20 | awaiting T+20 | $3.95 (−6.40%) |
Oct 21, 2026 11d ago | DEF 14A | $3.86 | awaiting T+20 | awaiting T+20 | $3.95 (+2.33%) |
Oct 14, 2026 18d ago | 8-K | $3.90 | awaiting T+20 | awaiting T+20 | $3.95 (+1.28%) |
Oct 5, 2026 27d ago | 8-K | $4.33 | awaiting T+20 | awaiting T+20 | $3.95 (−8.78%) |
Sep 24, 2026 5w ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Sep 24, 2026 5w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $3.95 (−1.28%) |
Jul 21, 2026 14w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $3.95 (−22.40%) |
Jun 11, 2026 20w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $3.95 (+2.33%) |
Jun 4, 2026 21w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $3.95 (−12.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers